Therapy of chronic hepatitis B: focus on telbivudine
Therapy of chronic hepatitis B: focus on telbivudine
复制标题
DOI：
10.1016/s1590-8658(07)60017-6
复制
发表时间：
2007-11-01
影响因子：
4.5
通讯作者：
Stornaiuolo, Gianfranca
中科院分区：
文献类型：
--
作者：
Gaeta, Giovanni Battista;Stornaiuolo, Gianfranca
乙型肝炎病毒（HBV）病毒载量与坏死性炎症和慢性乙型肝炎的预后密切相关。减少病毒载量从而改善预后的现有治疗方案要么基于干扰素，要么基于抑制HBV DNA复制的核苷/核苷酸类似物抗病毒药物。使用IFN - α或聚乙二醇化IFN - α -2a的时间超过48周受到其副作用的限制。抗病毒药物具有更可接受的副作用，拉米夫定是第一种可用的抗病毒药物，它被广泛使用，直到它明显具有很高的耐药性出现的可能性，这迅速抵消了它的益处。一种新的抗病毒药物替比夫定已在美国和欧洲获得批准，似乎对HBV具有非常快速和有效的作用，具有良好的安全性。(C) 2007年意大利胃肠病学出版社，Elsevier Ltd.出版版权所有。
Hepatitis B virus (HBV) viral load is closely related to necroinflammation and the outcome of chronic hepatitis B. The available treatment options to reduce viral load, and hence improve outcome, are either based on IFN or on nucleoside/nucleotide analogue antiviral agents, which inhibit HBV DNA replication. Use of IFN alfa or pegylated IFN alfa-2a for periods longer than 48 weeks is limited by their side-effects. The antiviral agents have much more acceptable side-effect profiles, and lamivudine, the first antiviral to become available, was widely used until it became apparent that it carries a high potential for resistance to emerge, which rapidly negates its benefit. A new antiviral agent, telbivudine, has been approved in the USA and Europe and appears to be very rapid and potent against HBV, with an excellent safety profile. (C) 2007 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. All rights reserved.